Verastem reported $59.01M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Alaunos Therapeutics USD 1.19M 148K Sep/2025
AstraZeneca USD 8.18B 4.35B Mar/2026
Curis USD 9.02M 23.01M Dec/2025
Cytokinetics USD 200.58M 4.46M Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
Incyte USD 5.62B 4.5B Mar/2026
Laboratory Of America USD 3.13B 6.3M Mar/2026
Novartis USD 9.29B 507M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
TG Therapeutics USD 170.12M 28.04M Mar/2026
Verastem USD 59.01M 21.98M Dec/2025